{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:12Z","timestamp":1792021632722,"version":"4.4.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.medj.2024.10.022","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T10:37:12Z","timestamp":1734086232000},"page":"1452-1455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma"],"prefix":"10.1016","volume":"5","author":[{"given":"Santi","family":"Nolasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.10.022_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype","author":"Jackson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.022_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.10.022_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic Therapies for Severe Asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.022_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2024.10.022_bib5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.medj.2024.10.022_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2024.08.033","article-title":"Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study","author":"Crimi","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.medj.2024.10.022_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.medj.2024.10.022_bib9","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1164\/rccm.202308-1413LE","article-title":"Benralizumab Normalizes Sputum Eosinophilia in Severe Asthma Uncontrolled by Anti-IL-5 Antibodies: A Single-Blind, Placebo-controlled Clinical Trial","volume":"208","author":"Mukherjee","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.medj.2024.10.022_bib10","doi-asserted-by":"crossref","first-page":"2000117","DOI":"10.1183\/13993003.00117-2020","article-title":"Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena","volume":"56","author":"Mukherjee","year":"2020","journal-title":"Eur. Respir. J."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:08:17Z","timestamp":1765595297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024004203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2666634024004203"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.022","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}